Drug intelligence / Profile preview

ZK-806450

Development stage: Preclinical
Modality: Small Molecules

Overview

ZK-806450 is an experimental small molecule compound classified as a carbazole derivative. It has been investigated primarily as a potent inhibitor of factor Xa, a key serine protease in the coagulation cascade, and thus may have potential applications as an anticoagulant. Additionally, ZK-806450 has demonstrated antiviral activity in vitro, with high binding potential to the allosteric binding site of the SARS-CoV-2 3CL protease. The compound is not approved for clinical use and has not advanced beyond preclinical or early research stages[1][2][3][9].

Targets

Mpro (3C-like proteinase of SARS-CoV-2)F10 (Factor Xa)

Beyond the preview

Go deeper on ZK-806450.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZK-806450.

Explore the full profile